Respiratory infections constitute one of the most pervasive categories of infectious disease encountered across all clinical settings and age groups, collectively generating an extraordinary global burden of morbidity, mortality, and healthcare resource consumption that places them among the most clinically and economically significant conditions in medicine. The respiratory tract, extending from the nasal mucosa and pharynx of the upper airways through the larynx, trachea, bronchi, and bronchioles to the alveolar air sacs of the lower airways, is continuously exposed to the external environment through the essential physiological process of breathing, inhaling microorganisms suspended in airborne droplets and aerosols with every breath. This constant environmental exposure makes the respiratory tract the most common site of infectious disease in humans and the primary portal of entry for many of the most clinically important viral and bacterial pathogens encountered in clinical practice.
The global burden of respiratory infections is staggering. Acute lower respiratory infections, comprising community-acquired pneumonia, bronchiolitis, and related lower airway infections, are the leading infectious cause of death worldwide and the third leading cause of death from any cause after ischemic heart disease and stroke, killing approximately 2.5 million people annually even in the post-antibiotic era. The 2009 influenza pandemic, the 2003 SARS epidemic, and most recently the COVID-19 pandemic caused by SARS-CoV-2 have demonstrated with devastating clarity the capacity of respiratory viral pathogens to produce explosive global spread and overwhelming healthcare system burden through the airborne and droplet transmission that makes respiratory infections uniquely capable of rapid community dissemination. Upper respiratory tract infections, while carrying far lower individual mortality risk than pneumonia, generate the greatest total volume of medical consultations and antibiotic prescriptions of any infection category, contributing substantially to the global antimicrobial resistance crisis through the massive and largely unnecessary antibiotic prescribing for viral upper respiratory tract infections that constitutes the single largest driver of resistance selection in community-acquired bacterial pathogens.
The classification of respiratory infections into upper and lower respiratory tract categories reflects both the anatomical site of predominant involvement and the clinical severity typically associated with each category, though this anatomical boundary is frequently crossed by infections that begin in the upper respiratory tract and extend to involve the lower airways in vulnerable individuals. Upper respiratory tract infections, encompassing the common cold, rhinosinusitis, pharyngitis, tonsillitis, otitis media, epiglottitis, and laryngotracheobronchitis, are predominantly caused by viruses and typically produce the self-limited illnesses familiar to virtually every adult from personal experience. Lower respiratory tract infections, encompassing pneumonia, acute bronchitis, acute exacerbations of chronic obstructive pulmonary disease, bronchiolitis, and lung abscess, carry a substantially greater risk of severe illness, hospitalization, and death, particularly in the elderly, very young children, and immunocompromised individuals, and require more aggressive diagnostic evaluation and treatment than most upper respiratory tract infections.
Common Cold and Rhinovirus Infections
The common cold, caused in the majority of cases by rhinoviruses of which more than one hundred distinct serotypes have been identified alongside contributions from coronaviruses, adenoviruses, respiratory syncytial virus, and parainfluenza viruses, is the most prevalent acute infectious illness in humans and the most common reason for seeking medical attention and taking time off work or school in developed countries. The extraordinary rhinovirus diversity, with different serotypes circulating simultaneously and sequentially throughout the year and with little cross-protective immunity between serotypes, explains the clinical observation that adults experience two to four colds per year and young children may experience six to eight, accumulating lifetime exposure to dozens of rhinovirus serotypes over decades without ever developing the broad cross-reactive immunity that would provide durable protection against this antigenically diverse group.
Rhinovirus replicates primarily in the ciliated epithelial cells of the nasal mucosa and nasopharynx, attaching to the intercellular adhesion molecule 1 receptor expressed on the apical surface of these cells in the case of the major receptor group rhinoviruses that comprise the majority of serotypes, and to low-density lipoprotein receptor family members in the case of the minor receptor group serotypes. The rhinovirus-triggered inflammatory response in the nasal mucosa, mediated by the innate immune recognition of viral RNA by toll-like receptor 3 and RIG-I pattern recognition receptors and the subsequent release of interleukin-8, bradykinin, and other inflammatory mediators, produces the nasal congestion, rhinorrhea, sneezing, and sore throat that constitute the characteristic symptom complex of the common cold through mechanisms of mucus hypersecretion, vascular leakage, and sensory nerve stimulation rather than direct viral cytopathic destruction of epithelial cells. This inflammatory rather than cytopathic mechanism explains why the common cold resolves despite the continuing presence of viable virus in the nasal secretions and why anti-inflammatory rather than antiviral approaches might theoretically provide symptomatic benefit, a hypothesis that has unfortunately not translated into effective clinical treatments.
The management of the common cold is fundamentally symptomatic, because no antiviral therapy with meaningful clinical efficacy has been demonstrated for rhinovirus infections in adequately powered randomized controlled trials, and because the illness is in most cases mild, self-limited, and resolved within seven to ten days without specific treatment in immunocompetent individuals. Over-the-counter symptomatic treatments including decongestants for nasal congestion, antihistamines for rhinorrhea, analgesics and antipyretics for sore throat and fever, and antitussives and expectorants for cough provide partial and temporary relief of individual symptoms, with the evidence base for each agent varying from modest to minimal in rigorous clinical trials. The most important management principle for common cold in clinical practice is the avoidance of antibiotic prescribing for viral upper respiratory tract infections, which represents the most prevalent form of antibiotic misuse in outpatient medicine and which produces no clinical benefit while selecting for antimicrobial resistant bacteria in both the individual patient and the broader community.
Pneumonia: Classification, Pathogens and Management
Community-acquired pneumonia, the acute infectious inflammation of the lung parenchyma occurring in individuals who have not been recently hospitalized or institutionalized, is caused by a diverse spectrum of bacterial, viral, fungal, and atypical microbial pathogens whose relative prevalences vary with patient age, immune status, geographic location, and the season of the year. Streptococcus pneumoniae, the pneumococcus, remains the most commonly identified bacterial cause of community-acquired pneumonia across all age groups and severity levels in studies employing comprehensive microbiological evaluation, causing pneumonia through its elaboration of pneumolysin and other virulence factors that damage alveolar epithelial cells and the alveolar macrophages that provide the first line of innate immune defense against inhaled pathogens. The clinical presentation of pneumococcal pneumonia, characterized by the abrupt onset of rigors, high fever, pleuritic chest pain, and productive cough with purulent or rust-colored sputum, represents the classic lobar pneumonia presentation whose recognition has anchored clinical pneumonia diagnosis for over a century.
Atypical pneumonias, caused by organisms including Mycoplasma pneumoniae, Chlamydia pneumoniae, Legionella pneumophila, and influenza virus, produce a clinical syndrome distinct from the classic pneumococcal presentation, with more gradual onset, milder constitutional symptoms, non-productive cough, bilateral and patchy rather than lobar radiographic infiltrates, and a clinical picture sometimes described as walking pneumonia because patients may not appear severely ill despite significant pulmonary infiltration. Mycoplasma pneumoniae, the most common cause of atypical pneumonia in young adults and school-age children, lacks a cell wall and is therefore intrinsically resistant to beta-lactam antibiotics, requiring treatment with macrolides, tetracyclines, or respiratory fluoroquinolones whose mechanisms of action do not depend on cell wall synthesis inhibition. Legionella pneumophila, transmitted through the inhalation of contaminated water aerosols from cooling towers, hot tubs, and hospital water systems rather than through person-to-person contact, produces severe pneumonia with high mortality that is particularly prevalent in immunocompromised, elderly, and smoking individuals, with the clinical clue of relative bradycardia, hyponatremia, and the characteristic urinary antigen test positivity that enables rapid diagnosis without awaiting culture results.
The severity assessment of community-acquired pneumonia using validated clinical prediction rules including the CURB-65 score and the Pneumonia Severity Index provides the evidence-based framework for determining the appropriate level of care, from outpatient treatment through general ward admission to intensive care unit management, that each patient requires. The CURB-65 score, assigning one point each for confusion, elevated blood urea nitrogen, elevated respiratory rate, low blood pressure, and age over sixty-five, provides a rapid bedside assessment that predicts thirty-day mortality and guides admission decisions, with patients scoring zero to one typically appropriate for outpatient treatment, those scoring two requiring consideration of hospitalization, and those scoring three or more requiring hospital admission with consideration of intensive care unit referral for the highest scores. The antibiotic treatment of community-acquired pneumonia is guided by the severity assessment, the likely pathogen spectrum based on clinical presentation and host characteristics, and local antimicrobial resistance patterns, with combination therapy including a beta-lactam and a macrolide or a respiratory fluoroquinolone monotherapy representing the standard empirical approach for most hospitalized patients.
Influenza and Viral Lower Respiratory Infections
Influenza A and B viruses produce the annual seasonal epidemics of influenza that cause substantial morbidity and mortality worldwide, with estimates of sixty thousand to one hundred thousand deaths annually in the United States alone from influenza and its complications, predominantly in elderly adults and immunocompromised individuals. The surface glycoproteins hemagglutinin and neuraminidase, which mediate influenza viral attachment to and release from respiratory epithelial cells respectively, are the primary targets of both humoral immune responses and antiviral medications, and their antigenic variation through the processes of antigenic drift and antigenic shift drives the need for annual influenza vaccine reformulation and creates the pandemic potential when novel hemagglutinin-neuraminidase combinations emerge against which the global population has no pre-existing immunity.
The antiviral treatment of influenza with neuraminidase inhibitors including oseltamivir and zanamivir, when initiated within forty-eight hours of symptom onset, reduces the duration of illness by approximately one to two days, reduces the severity of symptoms, and in high-risk patients reduces the risk of lower respiratory tract complications including pneumonia and hospitalization. The clinical value of antiviral treatment is greatest in the highest-risk populations including those over sixty-five years old, pregnant women, individuals with chronic medical conditions, and immunocompromised individuals, for whom even modest reductions in illness duration and complication risk translate into meaningful clinical benefit. The baloxavir marboxil, a cap-dependent endonuclease inhibitor that targets the viral RNA polymerase through a mechanism completely distinct from the neuraminidase inhibitors, provides an alternative antiviral option with the practical advantage of a single-dose regimen and with activity against oseltamivir-resistant influenza strains, broadening the therapeutic options available for influenza treatment.